EUCTR2007-000758-30-IT进行中（未招募）不适用
Randomized continuation, dose escalation trial of Sorafenib in pts with advanced HCC with radiological progression on prior sorafenib treatment (Phase II study) - ONC-2006-004
ISTITUTO CLINICO HUMANITAS0 个研究点开始时间: 2007年5月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •? Patients with advanced/inoperable HCC not eligible for radical or loco-regional therapies ? Male or female patients >= 18 years of age ? Life expectancy of at least 12 weeks at screening ? Histologically or cytologically documented HCC ? At least one tumor lesion that meets both of the following criteria: 1) The lesion is measurable as per RECIST criteria, and 2) The lesion has not been subject to previous loco-regional therapy (such as radiation therapy, TACE, TAE, PEI, RFA, or cryoablation) ? Patients previously treated with loco-regional treatments are eligible provided that previously treated lesions are not selected as target lesions. Local therapy must be completed at least 4 weeks prior to the baseline scan ? ECOG PS of 0, 1, or 2 (Appendix 9.1) ? Cirrhotic status of Child-Pugh class A or B (Appendix 9.5) ? Barcelona-Clinic Liver Cancer (BCLC) stage B or C (Appendix 9.6) ? The following laboratory parameters: - Platelet count >= 60 x 109 /L - Haemoglobin >= 8.5 g/dL - Total bilirubin <= 3 mg/dL - Alanine transaminase (ALT) and Aspartato transaminase (AST) <= 5 x upper limit of normal - Amylase and lipase < 1.5 x the upper limit of normal - Serum creatinine <= 1.5 x the upper limit of normal - Prothrombin time (PT)-international normalized ratio (INR) < 2.3 or PT < 6 seconds above control. Patients who are being therapeutically anticoagulated with an agent such as Coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists. ? Written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Previous or concurrent cancer that is distinct in primary site or histology from HCC, except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis & T1). Any cancer curatively treated > 3 years prior to entry is permitted • Renal failure requiring hemo- or peritoneal dialysis • History of cardiac disease: congestive heart failure > New York Heart Association (NYHA) class 2; active coronary artery disease (CAD); cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers ordigoxin), or uncontrolled hypertension. Myocardial infarction more than 6 months prior to study entry is permitted if there is no evidence of active CAD • Active clinically serious infections (> Grade 2 [NCI CTCAE] version 3.0) • Known history of human immunodeficiency virus (HIV) infection • Known Central Nervous System tumors including metastatic brain disease • Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry • History of organ allograft • Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results • Patients unable to swallow oral medications • Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study • Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial
研究者
相似试验
尚未招募
不适用
Dose escalation study for inoperable esophageal cancer patients.inoperable oesophageal tumorsdefinitive chemoradiationdose escalationNL-OMON25587dept of Radiotherapy, AMC, AmsterdamArhems Radiotherapeutisch Institute, Arnhemdept of oncology, Erasmusmc, Rotterdam260
已完成
3 期
A Randomized Trial of Dose Escalation in definitive Chemoradiotherapy for patients with Oesophageal cancer *ART DECO*esophagus cancerOesophageal cancer10017990NL-OMON41614Academisch Medisch Centrum260
进行中（未招募）
不适用
A Dose-Escalation, Randomized Phase I/II trial of Zalutumumab - a Human Monoclonal Anti-EGF receptor Antibody - With or Without Irinotecan chemotherapy in Cetuximab refractory Colorectal Cancer patients Who Have Failed Standard Chemotherapy and Progressed During or Within 6 months of Stopping Cetuximab-Based Therapy. - Zalutumumab with or without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal CancerEUCTR2007-005690-59-BEGenmab A/S97
已完成
不适用
Randomized control trial of increased dose therapy with Entecavir vursus combination therapy with Entecavir and Adefovir in CHB patients with inadequate nucleoside analogue therapyChronic hepatitis BJPRN-UMIN000003982Hyogo College Of Medicine60
进行中（未招募）
1 期
A study to look at different types and doses of medications called inhaled corticosteroids (ICS), and compare how they effect the lungs. ICS drugs are a common treatment for asthma and have an anti-inflammatory effect in the airways of the lungs.AsthmaEUCTR2016-003002-14-DEGlaxoSmithKline Research & Development Limited48